Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.
Moreau P, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, Hajek R, Špička I, Baker R, Kim K, Martinez G, Min CK, Pour L, Leleu X, Oriol A, Koh Y, Suzuki K, Risse ML, Asset G, Macé S, Martin T; IKEMA study group. Moreau P, et al. Lancet. 2021 Jun 19;397(10292):2361-2371. doi: 10.1016/S0140-6736(21)00592-4. Epub 2021 Jun 4. Lancet. 2021. PMID: 34097854 Clinical Trial.
Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis.
Dimopoulos MA, Moreau P, Augustson B, Castro N, Pika T, Delimpasi S, De la Rubia J, Maiolino A, Reiman T, Martinez-Lopez J, Martin T, Mikhael J, Yong K, Risse ML, Asset G, Marion S, Hajek R. Dimopoulos MA, et al. Am J Hematol. 2023 Jan;98(1):E15-E19. doi: 10.1002/ajh.26602. Epub 2022 Jun 4. Am J Hematol. 2023. PMID: 35604280 Free PMC article. No abstract available.
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.
Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Qi M, Schecter J, Amin H, Qin X, Deraedt W, Ahmadi T, Spencer A, Sonneveld P; CASTOR Investigators. Palumbo A, et al. N Engl J Med. 2016 Aug 25;375(8):754-66. doi: 10.1056/NEJMoa1606038. N Engl J Med. 2016. PMID: 27557302 Free article. Clinical Trial.
Everolimus as a single agent in refractory or relapsed Hodgkin's lymphoma: the Brazilian Named Patient Program Experience.
Rocha TMBDSD, Fortier SC, Fischer TRDC, Perini GF, Gaiolla RD, Fogliatto L, Delamain MT, Costa AFD, Castro NS, Barretos WG, Souza CA, Buccheri V, Chiattone CS. Rocha TMBDSD, et al. Among authors: castro ns. Rev Bras Hematol Hemoter. 2017 Jul-Sep;39(3):216-222. doi: 10.1016/j.bjhh.2017.03.008. Epub 2017 May 11. Rev Bras Hematol Hemoter. 2017. PMID: 28830600 Free PMC article.
Treatment patterns and outcomes for Hodgkin Lymphoma patients aged 60 and older: a report from the Brazilian Prospective Hodgkin Lymphoma Registry.
Goveia L, Castro N, de Souza C, Colaço Villarim C, Traina F, Chiattone CS, Praxedes M, Solza C, Perobelli L, Baiocchi O, Gaiolla R, Boquimpani C, Buccheri V, Bonamin Sola C, de Oliveira Paula E Silva R, Ribas AC, Steffenello G, Pagnano K, Soares A, Souza Medina S, Silveira T, Zattar Cecyn K, Carvalho Palma L, de Oliveira Marques M, Spector N, Biasoli I. Goveia L, et al. Ann Hematol. 2023 Oct;102(10):2815-2822. doi: 10.1007/s00277-023-05352-w. Epub 2023 Jul 21. Ann Hematol. 2023. PMID: 37474632
Treatment outcomes for Hodgkin lymphoma: First report from the Brazilian Prospective Registry.
Biasoli I, Castro N, Delamain M, Silveira T, Farley J, Simões BP, Solza C, Praxedes M, Baiocchi O, Gaiolla R, Franceschi F, Sola CB, Boquimpani C, Clementino N, Perini G, Pagnano K, Steffenello G, Tabacof J, de Freitas Colli G, Soares A, de Souza C, Chiattone CS, Milito C, Morais JC, Spector N. Biasoli I, et al. Hematol Oncol. 2018 Feb;36(1):189-195. doi: 10.1002/hon.2450. Epub 2017 Jun 23. Hematol Oncol. 2018. PMID: 28643458
Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study.
Jurczak W, Moreira I, Kanakasetty GB, Munhoz E, Echeveste MA, Giri P, Castro N, Pereira J, Akria L, Alexeev S, Osmanov E, Zhu P, Alexandrova S, Zubel A, Harlin O, Amersdorffer J. Jurczak W, et al. Lancet Haematol. 2017 Aug;4(8):e350-e361. doi: 10.1016/S2352-3026(17)30106-0. Epub 2017 Jul 14. Lancet Haematol. 2017. PMID: 28712941 Clinical Trial.
Lower socioeconomic status is independently associated with shorter survival in Hodgkin Lymphoma patients-An analysis from the Brazilian Hodgkin Lymphoma Registry.
Biasoli I, Castro N, Delamain M, Silveira T, Farley J, Pinto Simões B, Solza C, Praxedes M, Baiocchi O, Gaiolla R, Franceschi F, Bonamin Sola C, Boquimpani C, Clementino N, Fleury Perini G, Pagnano K, Steffenello G, Tabacof J, de Freitas Colli G, Soares A, de Souza C, Chiattone CS, Raggio Luiz R, Milito C, Morais JC, Spector N. Biasoli I, et al. Int J Cancer. 2018 Mar 1;142(5):883-890. doi: 10.1002/ijc.31096. Epub 2017 Oct 26. Int J Cancer. 2018. PMID: 29023692
Six cases of leprosy associated with allogeneic hematopoietic SCT.
Pieroni F, Stracieri AB, Moraes DA, Paton EJ, Saggioro FP, Barros GM, Barros JC, Oliveira MC, Coutinho MA, Castro NS, Vigoritto AC, Trabasso P, Souza CA, de Souza MP, Mauad MA, Colturato VA, Simões BP, Foss NP, Voltarelli JC. Pieroni F, et al. Among authors: castro ns. Bone Marrow Transplant. 2007 Nov;40(9):859-63. doi: 10.1038/sj.bmt.1705824. Epub 2007 Aug 27. Bone Marrow Transplant. 2007. PMID: 17724445
23 results